Should diabetic patients treated long-term with sulfonylureas be switched to nateglinide?
Sevinc
Alper
A
Gaziantep University School of Medicine, Department of Internal Medicine, Gaziantep, Turkey. sevinc@gantep.edu.tr
D000328:Adult; D001786:Blood Glucose / Q000187:drug effects; D003510:Cyclohexanes / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013995:Time
D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D000077715:Nateglinide; D010649:Phenylalanine